[1]
Barba, T., Marquet, A., Bouvry, D., Cohen-Aubart, F., Ruivard, M., Debarbieux, S., Khouatra, C., Vighetto, A., de Parisot, A., Valeyre, D. and Sève, P. 2018. Efficacy and safety of infliximab therapy in refractory upper respiratory tract sarcoidosis: experience from the STAT registry. Sarcoidosis, Vasculitis and Diffuse Lung Disease. 34, 4 (Feb. 2018), 343–351. DOI:https://doi.org/10.36141/svdld.v34i4.5817.